Anoxic waters

GCANRx Announces Completion of Preclinical Study for Neuropsychiatric Cannabinoid Therapy

Retrieved on: 
Tuesday, February 27, 2024
Therapy, Reactive oxygen species, Alzheimer's disease, MicroRNA, Inflammation, OTC, LPS, Schizophrenia, Nitric oxide, Cell, Factorization of polynomials, Safety, Protein, Clinical trial, Gene, DSM-IV codes, ROS, Hebrew University of Jerusalem, Microglia, Anoxic waters, Spectrum, Al-Quds, Research, Cannabidiol, Pharmaceutical industry

Professor Tal Burstyn-Cohen, Ph.D. of the Hebrew University, through the Yissum Research Development Company, led the preclinical study.

Key Points: 
  • Professor Tal Burstyn-Cohen, Ph.D. of the Hebrew University, through the Yissum Research Development Company, led the preclinical study.
  • The preclinical study aimed to assess the impact of various combinations of the neuroprotective therapeutic in a preclinical model.
  • “We are excited to finally receive the positive results from our preclinical study, which was our first step in validating our novel, cannabinoid based therapeutic,” said Aitan Zacharin, GCANRx CEO.
  • To receive the latest information about GCANRx sign up to the investor email at https://bit.ly/2ZNlBoj or follow @GCANRX on Twitter.

RS Oncology presents new drug in early clinical development for Mesothelioma and lung cancer patients

Retrieved on: 
Thursday, August 3, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Anoxic waters, IMIG, Medical laboratory, University, University of Leicester, Mitochondrion, University Hospitals Cleveland Medical Center, Cancer, Quality of life, John Cunniff, Therapy, Multimedia, Research, Assistant, MPE, Science, PRX, ROS, Oxidative stress, University Hospitals of Leicester NHS Trust, RSO, Patient, Pathology, RS, Mesothelioma, NIHR, Science Publishing Group, Reactive oxygen species, Safety, Pharmaceutical industry

RS Oncology is bringing exciting new science to patients who will have the best chance of benefiting from new therapies.

Key Points: 
  • RS Oncology is bringing exciting new science to patients who will have the best chance of benefiting from new therapies.
  • PRX3 is a novel drug target with potential for treating patients with the asbestos related cancer, mesothelioma.
  • “PRX3 is a novel and interesting therapeutic drug target with potential for treating cancers, especially those with unmet need such as mesothelioma.
  • We await the first clinical results with interest.”
    For more information about MITOPE clinical trial visit Mesothelioma UK .

JCRI-ABTS and USMI Reports Statistically Significant Results of the Canady Helios Cold Plasma Phase 1 Clinical Trial on Patients with Stage 4 and Recurrent Advanced Solid Tumors

Retrieved on: 
Thursday, June 15, 2023
Other Health, Research, General Health, Oncology, Medical Devices, Clinical Trials, Science, Surgery, Biotechnology, Alternative Medicine, FDA, Health, Anoxic waters, DNA, Radiation, IRE, Cell death, RNS, Safety, CAP, Survival, Cancer, Ovary, Breast, Global health, Reactive nitrogen species, Human embryonic stem cells clinical trials, Prostate, Treatment of lung cancer, Immunotherapy, CHCP, Messenger, Glioblastoma, ASCO, Irreversible electroporation, ROS, Sarcoma, SMC, Clinical trial, LRR, Patient, Risk, Melanoma, Sheba Medical Center, Plasma, Annual general meeting, Education minister, IDE, Rush University Medical Center, RUMC, Reactive oxygen species, Society, Medical imaging

(ClinicalTrials.gov identifier: NCT04267575)

Key Points: 
  • (ClinicalTrials.gov identifier: NCT04267575)
    Cancer remains a significant global health challenge, with over 1.9 million new cases and 608,570 cancer-related fatalities in the United States in 2021.
  • USMI’s Canady Helios Cold Plasma (CHCP) system, a non-thermal (26-30°C) and non-contact Cold Atmospheric Plasma (CAP) jet, offers a promising solution.
  • Twenty patients ranging from 26-85 years of age undergoing surgery for advanced stage 4 or recurrent solid tumors were enrolled.
  • Patients with preoperative treatments such as neoadjuvant chemotherapy, immunotherapy, radiation, and previous surgery were eligible.

GENFIT Further Strengthens its ACLF Franchise with a Third Clinical-Stage Asset

Retrieved on: 
Wednesday, May 31, 2023
Anoxic waters, US Foods, Heart failure, Hepatology, IQVIA, Inflammation, NTZ, LPS, SOC, Liver, Fibrosis, Kidney, ROS, Orphan drug, Investigational New Drug, Acquisition, Patient, Standard of care, Apoptosis, Ascites, ASK1, Multi, FDA, Therapy, IND, Safety, Pharmaceutical industry, Vaccine, Dietary supplement, ACLF, Euronext

ACLF is a complex disorder that will likely require the combination of different approaches and with this acquisition, we continue to strengthen our leadership in this indication.

Key Points: 
  • ACLF is a complex disorder that will likely require the combination of different approaches and with this acquisition, we continue to strengthen our leadership in this indication.
  • We now have a unique portfolio of three differentiated clinical stage programs in ACLF.
  • It is planned that approximately 60 adult patients with ACLF grades 1 and 2 will be enrolled in this trial.
  • Data expected to be available in the first half of 2024 should support preparation of further testing of efficacy.